newsfilter
← Latest News
Business Wire·

Baxalta Receives Positive CHMP Opinion for Use of ONCASPAR (pegaspargase) in European Union as a Component of Combination Therapy in Acute Lymphoblastic Leukaemia (ALL)

BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for use of ONCASPAR as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.